We next determined whether the effect of G9a inhibition, including with UNC0642, a second-generation derivative of UNC0638 optimized for high selectivity and in vivo potency against G9a and GLP [6], is more profound in the lymphoblastic lineage compared to other leukemias (e.g., myeloid) or cancer types. The gene discussed is EHMT2; the disease is cancer.